Haemonetics (HAE)
(Delayed Data from NYSE)
$74.97 USD
+0.52 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $74.98 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum D VGM
Price, Consensus and EPS Surprise
HAE 74.97 +0.52(0.70%)
Will HAE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for HAE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HAE
Robust Plasma Sales, New Innovations Aid Haemonetics Stock
HAE vs. BSX: Which Stock Is the Better Value Option?
HAE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Add HAE Stock in Your Portfolio Now
Zacks Industry Outlook Highlights Boston Scientific, Baxter International, Haemonetics and Phibro Animal Health
4 Medical Product Stocks to Buy From a Prospective Industry
Other News for HAE
Haemonetics Corp (HAE) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
Haemonetics Corp (HAE) Shares Up 4.79% on Sep 27
Notable Thursday Option Activity: HAE, BA, PGY
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
Haemonetics Corp (HAE) Stock Price Up 3.5% on Sep 23